Holen Sie sich die Stockscreener-App
0.6866
0.65%
0.0111
Handel nachbörslich:
.69
0.0034
+0.50%
Schlusskurs vom Vortag:
$0.6755
Offen:
$0.6694
24-Stunden-Volumen:
4.50M
Relative Volume:
0.81
Marktkapitalisierung:
$207.15M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-134.84M
KGV:
-0.9155
EPS:
-0.75
Netto-Cashflow:
$-117.11M
1W Leistung:
-2.57%
1M Leistung:
+34.66%
6M Leistung:
-9.41%
1J Leistung:
-26.67%
1-Tages-Spanne:
$0.633
$0.6915
1-Wochen-Bereich:
$0.60
$0.7646
52-Wochen-Spanne:
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Firmenname
Sangamo Therapeutics Inc
Sektor
Branche
Telefon
(510) 970-6000
Adresse
501 CANAL BLVD., RICHMOND, CA
Vergleichen Sie SGMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.6866 | 203.80M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Hochstufung | Truist | Hold → Buy |
| 2024-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-01-07 | Fortgesetzt | Guggenheim | Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-12-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-09-08 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | SunTrust | Buy |
| 2019-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-10-10 | Eingeleitet | Guggenheim | Buy |
| 2018-06-20 | Eingeleitet | BofA/Merrill | Buy |
| 2017-11-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-01 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-10-19 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-10-23 | Fortgesetzt | Jefferies | Buy |
| 2013-05-03 | Eingeleitet | BioLogic Equity Research | Sell |
| 2011-02-23 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-07-29 | Bestätigt | Wedbush | Outperform |
| 2009-10-19 | Eingeleitet | Brean Murray | Sell |
| 2009-10-07 | Bestätigt | Leerink Swann | Outperform |
| 2009-08-25 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten
Published on: 2025-10-14 00:29:18 - newser.com
How Sangamo Therapeutics Inc. stock reacts to bond yieldsJuly 2025 Market Mood & Low Drawdown Investment Strategies - newser.com
Is Sangamo Therapeutics Inc. (GBY) stock a fit for income portfolios2025 Support & Resistance & Weekly Momentum Stock Picks - newser.com
Combining machine learning predictions for Sangamo Therapeutics Inc.July 2025 Sentiment & Stepwise Trade Execution Plans - newser.com
Combining price and volume data for Sangamo Therapeutics Inc.2025 Market Overview & Low Risk Growth Stock Ideas - newser.com
What machine learning models say about Sangamo Therapeutics Inc.Rate Cut & Reliable Breakout Forecasts - newser.com
Multi factor analysis applied to Sangamo Therapeutics Inc.2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
Published on: 2025-10-12 23:29:27 - newser.com
Will earnings trigger a reversal in Sangamo Therapeutics Inc.Entry Point & Free Verified High Yield Trade Plans - newser.com
Sangamo Therapeutics (NASDAQ:SGMO) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Volume spikes in Sangamo Therapeutics Inc. stock – what they meanWeekly Investment Summary & Community Consensus Stock Picks - newser.com
What analysts say about Sangamo Therapeutics Inc stockAnalyst Upgrades & Compound Your Gains With Quality Stocks - earlytimes.in
There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 28% Share Price Rise - simplywall.st
Visual trend scoring systems applied to Sangamo Therapeutics Inc.Weekly Profit Summary & Step-by-Step Swing Trade Plans - newser.com
Published on: 2025-10-06 03:38:37 - newser.com
Why Sangamo Therapeutics Inc. (GBY) stock stays on buy listsEarnings Miss & Weekly Breakout Stock Alerts - newser.com
Is Sangamo Therapeutics Inc. (GBY) stock a good hedge against inflationWeekly Market Outlook & Weekly High Return Stock Opportunities - newser.com
Published on: 2025-10-05 05:08:49 - newser.com
What hedge fund activity signals for Sangamo Therapeutics Inc. stock2025 Price Targets & High Return Stock Watch Alerts - newser.com
Published on: 2025-10-05 02:36:48 - newser.com
Published on: 2025-10-03 07:10:00 - newser.com
How to monitor Sangamo Therapeutics Inc. with trend dashboards2025 Performance Recap & Fast Entry High Yield Tips - newser.com
Why Sangamo Therapeutics Inc. (GBY) stock stays resilientEarnings Miss & Expert Verified Movement Alerts - newser.com
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Sangamo Biosciences CFO Resigns, New Officer Appointed - MSN
BRIEF-Sangamo Therapeutics Appoints Nikunj Jain As Principal Accounting Officer – SEC Filing - NewsX
Sangamo Therapeutics appoints Nikunj Jain as principal accounting officerSEC filing - MarketScreener
Sangamo Therapeutics, Inc. Appoints Nikunj Jain as Principal Accounting Officer, Effective October 1, 2025 - MarketScreener
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 28% - 富途牛牛
What analysts say about Tomra Systems ASA TMRA stockStochastic Oscillator Alerts & Target Triple-Digit Stock Opportunities - earlytimes.in
Published on: 2025-09-29 00:48:43 - newser.com
Published on: 2025-09-28 22:48:05 - newser.com
Can Olympia Industries Limited Maintain Its Share of Global Market for Its ProductBollinger Bands Signals & Exceptional Capital Growth - earlytimes.in
Finanzdaten der Sangamo Therapeutics Inc-Aktie (SGMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):